News

2025 Annual Update

2025 Annual Update

by | Nov 28, 2025 | Clinician Newsletters, Newsletters

Welcome to the 2025 update. BADBIR is a world leading pharmacovigilance Register for psoriasis built through the collective effort of the UK and Ireland dermatology community.  While we prepare an accessible version of the update available here, you can download a...

BDNG Annual Conference 2025, Harrogate

by | Sep 15, 2025 | News

Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, Catherine H Smith, Richard B Warren, Christopher E M Griffiths, BADBIR study groupBritish Journal of Dermatology, ljaf017, https://doi.org/10.1093/bjd/ljaf017  Related Oras A Alabas, Kayleigh J...

Taltz (ixekizumab) recruitment ends on 31st July 2025

Taltz (ixekizumab) recruitment ends on 31st July 2025

by | Jul 18, 2025 | News

Please be aware that BADBIR cannot accept any new registrations at baseline for patients starting Taltz after 31st July. Participants must have started treatment and provided consent before 1st August to be accepted. If participants signed consent and commenced Taltz...

Ustekinumab biosimilars

by | Jul 18, 2025 | Uncategorised

Since the patent for Stelara (ustekinumab) expired in 2024, there are now four ustekinumab biosimilars available in the UK:PyzchivaSteqeymaUzpruvoWenzelaWe expect that the majority of the patients on BADBIR who are currently taking Stelara will switch to one of the...

We’ll be at the BAD Annual Meeting in Glasgow

by | May 29, 2025 | News

We will be at the BAD Annual Meeting in Glasgow from the 1st to the 3rd July - come visit us at our stand!You can also attend one of our talks:- Tuesday, 1st July at 10:30 - Prof Warren & Dr Oras Alabas - Hot Topics - Update on new data to inform clinicians on use...

Changes to conventional cohort eligibility criteria

by | May 8, 2025 | News

As part of the 14th Substantial Amendment for the study, there have been some changes to the eligibility criteria for patients on conventional treatments. The implementation date for Substantial Amendment 14 is 08/05/2025; these changes will affect any patients...

Amendment 14

by | Apr 8, 2025 | Amendments

Study Amendment 14 to BADBIR has an implementation date of 8th May 2025.Documents in this amendmentYou can download all of the files for this amendment in one go using the link below (.zip file). If you would like the tracked changes versions of the documents to see...

Taltz (ixekizumab) recruitment has restarted

by | Dec 12, 2024 | News

If a patient recently started on Taltz meets all of our eligibility criteria, they can be recruited.We will review patients who switched from the Conventional cohort onto Taltz, where we have paused their cohort; these patients will now be able to be switched.Please...